Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 158

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

First-in-human high-cumulative-dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline

Open access
Averyanov, Alexander, Koroleva, Irina, Konoplyannikov, Mikhail, Revkova, Veronika, Lesnyak, Victor, Kalsin, Vladimir, Danilevskaya, Olesya, Nikitin, Alexey, Sotnikova, Anna, Kotova, Svetlana, Baklaushev, Vladimir·2020·Stem Cells Translational Medicine

Abstract

Previous phase I studies demonstrated safety and some beneficial effects of mesenchymal stem cells (MSCs) in patients with mild to moderate idiopathic pulmonary fibrosis (IPF). The aim of our study was to evaluate the safety, tolerability, and efficacy of a high cumulative dose of bone marrow MSCs in patients with rapid progressive course of severe to moderate IPF. Twenty patients with forced ventilation capacity (FVC) ≥40% and diffusing capacity of the lung for carbon monoxide (DLCO) ≥20% with a decline of both >10% over the previous 12 months were randomized into two groups: one group received two intravenous doses of allogeneic MSCs (2 × 108 cells) every 3 months, and the second group received a placebo. A total amount of 1.6 × 109 MSCs had been administered to each patient after the study completion. There were no significant adverse effects after administration of MSCs in any patients. In the group of MSC therapy, we observed significantly better improvement for the 6-minute walk distance in 13 weeks, for DLCO in 26 weeks, and for FVC in 39 weeks compared with placebo. FVC for 12 months in the MSCs therapy group increased by 7.8% from baseline, whereas it declined by 5.9% in the placebo group. We did not find differences between the groups in mortality (two patients died in each group) or any changes in the high-resolution computed tomography fibrosis score. In patients with IPF and a rapid pulmonary function decline, therapy with high doses of allogeneic MSCs is a safe and promising method to reduce disease progression. Lessons learned The primary objective was the evaluation of the safety and tolerability of repeated infusions of high doses of bone marrow-derived MSCs up to the total cumulative dose of 2 billion cells in subjects with rapidly progressing idiopathic pulmonary fibrosis. The evaluation was based on the number and severity of AEs related to the infusion during 52 weeks of follow-up. The secondary objective was evaluation of the main lung function parameters, such as forced ventilation capacity and diffusing capacity of the lung for carbon monoxide. The stem cell treatment has been found safe and well tolerable. Patients in the main group had their lung function increased, as compared to the placebo group, in which the continued decline of the lung function was observed. These findings allow us to conclude that such stem cell therapy is effective for the treatment of rapidly progressing idiopathic pulmonary fibrosis. Significance statementThe results of this first-in-human clinical trial revealed that a high cumulative dose of mesenchymal stem cells (MSCs) is safe and well tolerated by patients with idiopathic pulmonary fibrosis with a rapid lung function decline. During the treatment period, the patients in the main group experienced increased lung function; however, the patients in the placebo group experienced a continued decline in lung function. Thus, this study shows the safety, tolerability, and potential benefits of greater doses of MSCs than those used earlier in patients with idiopathic pulmonary fibrosis, and these findings might move future trials toward a new step in stem cells transplantation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/sctm.19-0037

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 158

Metadata

Authors
Averyanov, A., Koroleva, I., Konoplyannikov, M., Revkova, V., Lesnyak, V., Kalsin, V., Danilevskaya, O., Nikitin, A., Sotnikova, A., Kotova, S., & Baklaushev, V.
Venue
Stem Cells Translational Medicine
Published
2019-10-15
Volume
9
Issue
1
Pages
6-16
ISSN
  • 2157-6564 (ISSN-L)
  • 2157-6580
OpenAlex
W2981028433
Cited by
158
References
8
FWCI
13.01
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: First-in-human high-cumulative-dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline. https://app.cochat.ai/papers/10.1002/sctm.19-0037
The paper
Averyanov, A., Koroleva, I., Konoplyannikov, M., Revkova, V., Lesnyak, V., Kalsin, V., Danilevskaya, O., Nikitin, A., Sotnikova, A., Kotova, S., & Baklaushev, V. (2020). First-in-human high-cumulative-dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline. Stem Cells Translational Medicine. https://doi.org/10.1002/sctm.19-0037

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.